Bone Therapeutics ALLOB Phase I/IIA Delayed-Union Fracture Trial Update

Bone Therapeutics reports positive interim efficacy results in the 16-patient Phase I/IIA study of ALLOB® allogeneic bone cell therapy in the treatment of delayed-union fractures.

At six months following one percutaneous dose of ALLOB to the fracture site, all patients met the primary endpoint and exhibited statistically significant clinical...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us